USFDA classifies Lupin's Somerset facility as ‘Official Action Indicated’

18 Mar 2019 Evaluate

Lupin’s subsidiary -- Novel Laboratories’ Somerset facility has been cautioned by the United States Food and Drug Administration (USFDA) that it may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

The US Food and Drug Administration (USFDA) had conducted inspection at Somerset (New Jersey) facility in December 2018, and classified it as Official Action Indicated (OAI). ‘Official Action Indicated’, means approvals of pending applications or supplements from this site maybe withheld.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

1547.05 -46.60 (-2.92%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.